Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB Cause Type iv hypersensitivity reaction? 120 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 120 reports of Type iv hypersensitivity reaction have been filed in association with INFLIXIMAB (Renflexis). This represents 0.1% of all adverse event reports for INFLIXIMAB.

120
Reports of Type iv hypersensitivity reaction with INFLIXIMAB
0.1%
of all INFLIXIMAB reports
2
Deaths
55
Hospitalizations

How Dangerous Is Type iv hypersensitivity reaction From INFLIXIMAB?

Of the 120 reports, 2 (1.7%) resulted in death, 55 (45.8%) required hospitalization, and 6 (5.0%) were considered life-threatening.

Is Type iv hypersensitivity reaction Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB. However, 120 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB Cause?

Off label use (34,801) Drug ineffective (33,738) Condition aggravated (16,616) Rheumatoid arthritis (16,251) Pain (15,061) Fatigue (13,473) Arthralgia (13,441) Infusion related reaction (12,946) Product use issue (12,752) Drug intolerance (11,173)

What Other Drugs Cause Type iv hypersensitivity reaction?

AMOXICILLIN (165) CLINDAMYCIN (128) CEFACLOR (101) IBUPROFEN (98) AMPICILLIN (97) VANCOMYCIN (97) CEPHALEXIN (92) AMOXICILLIN\CLAVULANIC ACID (89) CEFUROXIME (82) CEFADROXIL (53)

Which INFLIXIMAB Alternatives Have Lower Type iv hypersensitivity reaction Risk?

INFLIXIMAB vs INFLIXIMAB-ABDA INFLIXIMAB vs INFLIXIMAB-AXXQ INFLIXIMAB vs INFLIXIMAB-DYYB INFLIXIMAB vs INFLIXIMAB-QBTX INFLIXIMAB vs INFLIXIMAB, RECOMBINANT

Related Pages

INFLIXIMAB Full Profile All Type iv hypersensitivity reaction Reports All Drugs Causing Type iv hypersensitivity reaction INFLIXIMAB Demographics